USPTO serial 79345190
STAT-X
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Jul 18, 2023
- Examiner
- AGREDA, SAMANTHA LEIGH
- Law office
- Historical data usage
What this means
Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.
Need help with STAT-X?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
SHENZHEN NEW INDUSTRIES BIOMEDICAL ENGINEERING CO., LTD.
CN
Other trademarks owned by SHENZHEN NEW INDUSTRIES BIOMEDICAL ENGINEERING CO., LTD.
SHENZHEN NEW INDUSTRIES BIOMEDICAL ENGINEERING CO., LTD.
CN
Other trademarks owned by SHENZHEN NEW INDUSTRIES BIOMEDICAL ENGINEERING CO., LTD.
SHENZHEN NEW INDUSTRIES BIOMEDICAL ENGINEERING CO., LTD.
CN
Other trademarks owned by SHENZHEN NEW INDUSTRIES BIOMEDICAL ENGINEERING CO., LTD.
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Stacy L. Emhoff
Stacy L. Emhoff Walker & Jocke Co., LPA231 South BroadwayMedina, OH 44256United StatesGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | [ Pharmaceutical preparations, namely, pharmaceutical preparations for the functional analysis of blood coagulation and fibrinolysis; Pharmaceutical preparations for the quantitative and qualitative detection of substances in human serum, plasma and body fluids; Chemico-pharmaceutical preparations for pharmaceutical purposes, namely, chemico-pharmaceutical preparations for pharmaceutical purposes for the functional analysis of blood coagulation and fibrinolysis; Chemico-pharmaceutical preparations for pharmaceutical purposes for the quantitative and qualitative detection of substances in human serum, plasma and body fluids; ] Medicated serums used for the functional analysis of blood coagulation and fibrinolysis; Medicated serums used for the quantitative and qualitative detection of analytes in human serum, plasma and body fluids; Medicines for serum therapy, namely, medicines for serum therapy for functional analysis of blood coagulation and fibrinolysis; Medicines for serum therapy for the quantitative and qualitative detection of substances in human serum, plasma and body fluids; Biological preparations for medical purposes, namely, biological preparations for medical purposes for the functional analysis of blood coagulation and fibrinolysis; Biological preparations for medical purposes for the quantitative and qualitative detection of substances in human serum, plasma and body fluids; Chemical preparations for pharmaceutical purposes, namely, chemical preparations for pharmaceutical purposes for the functional analysis of blood coagulation and fibrinolysis; Chemical preparations for pharmaceutical purposes for the quantitative and qualitative detection of substances in human serum, plasma and body fluids; chemical preparations for medical purposes, namely, chemical preparations for medical purposes for the functional analysis of blood coagulation and fibrinolysis; chemical preparations for medical purposes for the quantitative and qualitative detection of substances in human serum, plasma and body fluids; [ enzymes for medical purposes; enzyme preparations for medical purposes; Preparations for pharmaceutical purposes, namely, preparations for pharmaceutical purposes made of trace elements that are found in the human body for the functional analysis of blood coagulation and fibrinolysis; ] Preparations for pharmaceutical purposes made of trace elements that are found in the human body for the quantitative and qualitative detection of substances in human serum, plasma and body fluids; [ amino acids for medical purposes; preparations of microorganisms for medical or veterinary use; ] chemical preparations for the diagnosis of pregnancy; diagnostic preparations for medical purposes; [ reagent paper for medical purposes; ] diagnostic biomarker reagents for medical purposes; [ veterinary preparations for treatment of intestinal bacteria; medicines for veterinary purposes for treatment of intestinal bacteria; biological preparations for veterinary purposes for treatment of intestinal bacteria; chemical preparations for veterinary purposes for treatment of intestinal bacteria; enzymes for veterinary purposes; enzyme preparations for veterinary purposes; ] diagnostic preparations for veterinary purposes [ ; reagent paper for veterinary purposes ] | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by SHENZHEN NEW INDUSTRIES BIOMEDICAL ENGINEERING CO., LTD.
- Other trademarks owned by SHENZHEN NEW INDUSTRIES BIOMEDICAL ENGINEERING CO., LTD.
- Other trademarks owned by SHENZHEN NEW INDUSTRIES BIOMEDICAL ENGINEERING CO., LTD.
- Other trademarks in Class 005
- Similar marks named STAT-X
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Apr 19, 2026 | INPR | PARTIAL INVALIDATION OF REG EXT PROTECTION CREATED | — |
| Aug 26, 2025 | NURC | NOTICE OF UPDATED REGISTRATION CONFIRMATION EMAILED | — |
| Aug 6, 2025 | A7OK | AMENDMENT UNDER SECTION 7 - PROCESSED | — |
| Jun 5, 2025 | APRE | CASE ASSIGNED TO POST REGISTRATION PARALEGAL | — |
| Jan 16, 2025 | ES7R | TEAS SECTION 7 REQUEST RECEIVED | — |
| Dec 19, 2023 | FINO | FINAL DECISION TRANSACTION PROCESSED BY IB | — |
| Oct 19, 2023 | XXSS | GENERIC MADRID TRANSACTION SENT TO IB | — |
| Oct 19, 2023 | XXCR | GENERIC MADRID TRANSACTION CREATED | — |
| Oct 18, 2023 | FICR | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | — |
| Jul 18, 2023 | NRCC | NOTICE OF REGISTRATION CONFIRMATION EMAILED | — |
| Jul 18, 2023 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| May 2, 2023 | GPNX | NOTIFICATION PROCESSED BY IB | — |
| May 2, 2023 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| May 2, 2023 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Apr 12, 2023 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| Apr 12, 2023 | OP2R | NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB | — |
| Apr 12, 2023 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Mar 30, 2023 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Mar 30, 2023 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Mar 30, 2023 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Mar 30, 2023 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Jan 5, 2023 | RFNP | REFUSAL PROCESSED BY IB | — |
| Dec 9, 2022 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Dec 8, 2022 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Sep 28, 2022 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Sep 27, 2022 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Sep 21, 2022 | DOCK | ASSIGNED TO EXAMINER | — |
| Jul 19, 2022 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Jul 15, 2022 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Jul 14, 2022 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |